MNOV MediciNova

MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020

MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020
EN
13/10/2020

Underlying

MNOVMediciNova

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediciNova

 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial ...

MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND LA JOLLA, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding the Phase 2b/3 COMBAT clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients has been selected for a poster presentation at 36th International Symposium on ALS/MND to be held December ...

September 16, 2025 1 EN
 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova Provides Shareholder Update on Key Developments

MediciNova Provides Shareholder Update on Key Developments LA JOLLA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), provides a shareholder update recapping important developments for the Company. Standby Equity Purchase Agreement (SEPA) The Company reported the signing of a Standby Equity Purchase Agreement (SEPA) for up to $30 million worth of common stock over the course of 36 months. Under that Agr...

September 8, 2025 1 EN
 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova to Present at the H.C. Wainwright 27th Annual Global Invest...

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference LA JOLLA, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, MD., Ph.D., President and CEO, and David H. Crean, PhD, Chief Business Officer will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lot...

September 3, 2025 1 EN
 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial LA JOLLA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it successfully achieved enrollment of the target number of participants in its COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast). MN-166 is currently in development for the treatment of Amyotrophic Lateral Sclerosis (ALS). Dr. Yuichi Iwaki, MediciNova President and CEO commented, “This m...

August 26, 2025 1 EN
 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova Announces Signing of a Standby Equity Purchase Agreement fo...

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million LA JOLLA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces a Standby Equity Purchase Agreement (SEPA) for up to $30 million worth of common stock over the course of 36 months. Under the Agreement, the Company shall have the right, but not the obligation, to sell its common stock in individual transactions – or adva...

July 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch